RESUMEN

(1) Background: Acinetobacter baumannii has become the most important pathogen responsible for nosocomial infections in health systems. It expresses several resistance mechanisms, including the production of ß-lactamases, changes in the cell membrane, and the expression of efflux pumps. (2) Methods: A. baumannii was detected by PCR amplification of the blaOXA-51-like gene. Antimicrobial susceptibility to fluoroquinolones and aminoglycosides was assessed using the broth microdilution technique according to 2018 CLSI guidelines. Efflux pump system activity was assessed by the addition of a phenylalanine-arginine beta-naphthylamide (PAßN) inhibitor. (3) Results: A total of nineteen A. baumannii clinical isolates were included in the study. In an overall analysis, in the presence of PAßN, amikacin susceptibility rates changed from 84.2% to 100%; regarding tobramycin, they changed from 68.4% to 84.2%; for nalidixic acid, they changed from 73.7% to 79.0%; as per ciprofloxacin, they changed from 68.4% to 73.7%; and, for levofloxacin, they stayed as 79.0% in both groups. (4) Conclusions: The addition of PAßN demonstrated a decrease in the rates of resistance to antimicrobials from the family of quinolones and aminoglycosides. Efflux pumps play an important role in the emergence of multidrug-resistant A. baumannii strains, and their inhibition may be useful as adjunctive therapy against this pathogen.

RESUMEN

Carbapenem-resistant Acinetobacter baumannii is the top-ranked pathogen in the World Health Organization priority list of antibiotic-resistant bacteria. It emerged as a global pathogen due to the successful expansion of a few epidemic lineages, or international clones (ICs), producing acquired class D carbapenemases (OXA-type). During the past decade, however, reports regarding IC-I isolates in Latin America are scarce and are non-existent for IC-II and IC-III isolates. This study evaluates the molecular mechanisms of carbapenem resistance and the epidemiology of 80 non-duplicate clinical samples of A. baumannii collected from February 2014 through April 2016 at two tertiary care hospitals in Lima. Almost all isolates were carbapenem-resistant (97.5%), and susceptibility only remained high for colistin (95%). Pulsed-field gel electrophoresis showed two main clusters spread between both hospitals: cluster D containing 51 isolates (63.8%) associated with sequence type 2 (ST2) and carrying OXA-72, and cluster F containing 13 isolates (16.3%) associated with ST79 and also carrying OXA-72. ST2 and ST79 were endemic in at least one of the hospitals. ST1 and ST3 OXA-23-producing isolates were also identified. They accounted for sporadic hospital isolates. Interestingly, two isolates carried the novel OXA-253 variant of OXA-143 together with an upstream novel insertion sequence (ISAba47). While the predominant A. baumannii lineages in Latin America are linked to ST79, ST25, ST15, and ST1 producing OXA-23 enzymes, we report the emergence of highly resistant ST2 (IC-II) isolates in Peru producing OXA-72 and the first identification of ST3 isolates (IC-III) in Latin America, both considered a serious threat to public health worldwide.

Asunto(s)

RESUMEN

The aim of this study was to detect and characterize molecularly metallo-ß-lactamase (MßL) in clinical isolates of Pseudomonas aeruginosa. We carry out a cross sectional study in six publics hospital in Lima on August 2011. 51 isolates of P. aeruginosa resistant to ceftazidime and reduced susceptibility to carbapenemes were evaluated.The phenotypic assay was performed using the approximation method with substrate disks (ceftazidime, imipenem and meropenem) and ethylenediaminetetraacetic acid (EDTA). MßL gene detection was performed using the technique of polymerase chain reaction (PCR) multiplex. Through MßL detected phenotypic method in 15.7% of isolates. Detection of genes revealed the presence of the gene in the 8 isolates blaIMP. The first report of MßL in P. aeruginosa in Peru was described, this should alert the monitoring equipment in the institutions to promote control their spread.

Asunto(s)

RESUMEN

Con el objetivo de detectar y caracterizar molecularmente las metalo-ß-lactamasas (MßL) en aislamientos clínicos de Pseudomonas aeruginosa, se realizó un estudio trasversal en seis hospitales de referencia de Lima (Perú) en agosto de 2011. Se evaluó 51 aislamientos de P. aeruginosa, resistentes a ceftazidima y con sensibilidad reducida a carbapenémicos. El ensayo fenotípico se realizó con el método de aproximación de discos con sustratos (ceftazidima, imipenem y meropenem) y con ácido etilendiaminotetraacético (EDTA). La detección de genes MßL se realizó mediante la técnica de reacción en cadena de polimerasa multiplex. A través del método fenotípico se detectaron MßL en el 15,7% de los aislamientos, en todos ellos la detección de genes mostró la presencia del gen blaIMP. La descripción del primer reporte de MßL en aislamientos de P. aeruginosa en el Perú debería alertar a los equipos de vigilancia epidemiológica intrahospitalaria para promover su control y prevenir su diseminación.

The aim of this study was to detect and characterize molecularly metallo-ß-lactamase (MßL) in clinical isolates of Pseudomonas aeruginosa. We carry out a cross sectional study in six publics hospital in Lima on August 2011. 51 isolates of P. aeruginosa resistant to ceftazidime and reduced susceptibility to carbapenemes were evaluated.The phenotypic assay was performed using the approximation method with substrate disks (ceftazidime, imipenem and meropenem) and ethylenediaminetetraacetic acid (EDTA). MßL gene detection was performed using the technique of polymerase chain reaction (PCR) multiplex. Through MßL detected phenotypic method in 15.7% of isolates. Detection of genes revealed the presence of the gene in the 8 isolates blaIMP. The first report of MßL in P. aeruginosa in Peru was described, this should alert the monitoring equipment in the institutions to promote control their spread.

Asunto(s)

RESUMEN

La infección urinaria (ITU) es fácilmente manejada por el huésped normal pero puede causar problemas en pacientes inmunosuprimidos, requiriendo antimicrobianos en dosis bactericidas y no solo bacteriostáticas que aseguren tratamientos efectivos. En nuestro medio Ciprofloxacina es un antimicrobiano de uso frecuente en este tipo de infecciones, sin embargo no se evalúa de manera rutinaria el comportamiento de las cepas patógenas con respecto a parámetros microbiológicos como la Concentración Mínima Inhibitoria (CMI), menos aún la Concentración Mínima Bactericida (CMB). Objetivos: Determinar la relación entre la CMI y la CMB de Ciprofloxacina frente a gérmenes aislados a partir de ITU de pacientes hospitalizados y ambulatorios del INEN. Materiales y Métodos: Se aislaron 132 cepas de bacilos gramnegativos uropatógenos aislados de consultorio externo y pacientes hospitalizados, se determinó la susceptibilidad antimicrobiana de las cepas bacterianas usando la Concentración Mínima Inhibitoria por el método de macrodilución en caldo y posteriormente se determinó la Concentracion Mínima Bactericida por el método de dilución en agar. Resultados: Se detectó niveles de resistencia a Ciprofloxacina de 49 por ciento y 73 por ciento en cepas aisladas de pacientes de consultorio externo y pacientes hospitalizados,respectivamente. En el estudio se encontró una diferencia altamente significativa entre la CMB y la CMI tanto en cepas de pacientes hospitalizados como en cepas de consultorio externo (p<0.0001). Conclusiones: Resulta necesario implementar en los laboratorios microbiológicos métodos como la CMI y CMB, herramientas importantes para identificar características de la actividad antibacteriana de los antimicrobianos empleados en nuestro medio. De igual forma se debería evaluar el uso de las fluoroquinilonas, principalmente Ciprofloxacina en pacientes inmunosuprimidos restringiendo su administración para aquellos casos en que esté confirmada su susceptibilidad in vitro.

Asunto(s)